Hypoxia and hepatocellular carcinoma multidrug resistance in Progress_0.docVIP

 PAGE \* MERGEFORMAT 16 Hypoxia and hepatocellular carcinoma multidrug resistance in Progress [Keywords:] hypoxia, liver cancer, multidrug resistance Tumor cell multidrug resistance (multiple drug resistance, MDR) refers to the tumor cells after exposure to an anticancer drug, not only for drug resistance, other structures and mechanisms for a variety of different anticancer drugs can also produce cross-resistance. hepatocellular carcinoma is a common clinical cancer is not sensitive to chemotherapy, studies have confirmed that liver cancer chemotherapy multi-drug resistance is becoming invalid or failure of the main reasons. hepatocellular carcinoma multidrug resistant there are several mechanisms have, in recent years years, has been extensive literature on the liver cell hypoxia and the occurrence of liver cancer MDR mechanisms, clinical significance and other aspects of the in-depth study, this paper hypoxia and hepatocellular carcinoma multidrug resistance are reviewed. 1 hepatocellular carcinoma multidrug resistance generation mechanism MDR generation mechanism of liver cancer complicated, mainly in the following areas: (1) P170 glycoprotein (P-gP) P-gP on chromosome 7 by the multidrug resistance gene 1 (Multidrug Resistance Genel, MDR1) encoding glycoprotein, it is a molecular weight of 170KD, with energy-dependent “drug pump” function of the transmembrane glycoprotein, belonging to members of ABC transporter superfamily, which can take positive charge of intracellular lipid chemotherapy drugs against the pro- concentration of the pump to the cells, so chemotherapy drugs reach the intracellular concentration of the effective role of resistance [1]. (2) Multi-drug resistance-associated protein (MRP) 1992 years, from human small cell lung cancer cells lines H69AR MR gene was cloned, the encoded P190 protein, multidrug resistance-associated protein that is (MRP), an ABC transmembrane transporter protein superfamily, can mediate anthracycline, Ch